- Home
- BIIB vs CSGP Comparison
BIIB vs CSGP Comparison
Compare BIIB & CSGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CSGP
- Stock Information
- Founded
- BIIB 1978
- CSGP 1987
- Country
- BIIB United States
- CSGP United States
- Employees
- BIIB N/A
- CSGP 6152
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CSGP Business Services
- Sector
- BIIB Health Care
- CSGP Consumer Discretionary
- Exchange
- BIIB Nasdaq
- CSGP Nasdaq
- Market Cap
- BIIB 25.1B
- CSGP 32.9B
- IPO Year
- BIIB 1991
- CSGP 1998
- Fundamental
- Price
- BIIB $160.85
- CSGP $80.15
- Analyst Decision
- BIIB Buy
- CSGP Buy
- Analyst Count
- BIIB 25
- CSGP 12
- Target Price
- BIIB $258.57
- CSGP $93.25
- AVG Volume (30 Days)
- BIIB 1.7M
- CSGP 2.5M
- Earning Date
- BIIB 10-30-2024
- CSGP 10-22-2024
- Dividend Yield
- BIIB N/A
- CSGP N/A
- EPS Growth
- BIIB 10.05
- CSGP N/A
- EPS
- BIIB 11.06
- CSGP 0.43
- Revenue
- BIIB $9,607,500,000.00
- CSGP $2,666,900,000.00
- Revenue This Year
- BIIB N/A
- CSGP $13.32
- Revenue Next Year
- BIIB N/A
- CSGP $12.62
- P/E Ratio
- BIIB $14.54
- CSGP $186.42
- Revenue Growth
- BIIB N/A
- CSGP 11.67
- 52 Week Low
- BIIB $153.62
- CSGP $68.26
- 52 Week High
- BIIB $268.30
- CSGP $100.38
- Technical
- Relative Strength Index (RSI)
- BIIB 37.71
- CSGP 59.04
- Support Level
- BIIB $158.44
- CSGP $79.48
- Resistance Level
- BIIB $165.29
- CSGP $82.49
- Average True Range (ATR)
- BIIB 4.09
- CSGP 2.24
- MACD
- BIIB 1.04
- CSGP 0.58
- Stochastic Oscillator
- BIIB 32.51
- CSGP 80.03
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CSGP CoStar Group Inc.
CoStar Group is a leading provider of commercial real estate data and marketplace listing platforms. Its data offering contains in-depth analytical information on over 5 million commercial real estate properties related to various subsectors including office, retail, hotels, multifamily, healthcare, industrial, self-storage, and data centers. It operates many flagship brands such as CoStar Suite, LoopNet, Apartments.com, BizBuySell, and Lands of America, with more than 80% of its revenue classified as subscription-based. The company recently expanded its presence in Canada, the United Kingdom, Spain, and France.